Has Senan Sultan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,460,987 in general payments to Senan Sultan, MD across 2,410 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Senan Sultan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Senan Sultan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Senan Sultan, MD

Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1366461543

Payments from drug & device makers

$2,460,987in general payments, 2019–2025

Across 2,410 payments — averaging $1021.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$947K
Novo Nordisk AS$784K
AbbVie$328K
Amgen$178K
Sanofi-aventis U.S. LLC$78K
Endo Pharmaceuticals Inc.$72K
plus $74K from 53 others

$138,059in research payments, 2019–2025

Across 8 payments — averaging $17,257 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$138K
Novo Nordisk AS$50

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	41	$946,992
Novo Nordisk AS	1,347	$784,498
AbbVie	33	$328,443
Amgen(2 entities)	96	$178,032
Sanofi-aventis U.S. LLC	38	$77,780
Endo Pharmaceuticals Inc.	29	$71,512
Boehringer Ingelheim Pharma GmbH & Co.kg	3	$11,685
Sanofi US Services Inc.	2	$10,615
Lilly USA, LLC	55	$9,865
Astrazeneca UK Limited	2	$8,836
Boehringer Ingelheim	61	$8,199
AstraZeneca(2 entities)	43	$7,277
Tandem Diabetes Care, Inc.	17	$2,517
Abbott	130	$2,310
Tosoh Bioscience, Inc.	2	$1,566
Novo Nordisk	125	$1,556
Dexcom, Inc.	54	$1,320
Boehringer Ingelheim International GmbH	11	$1,206
Insulet Corporation	53	$1,079
Medtronic(2 entities)	43	$1,022
Radius Health, Inc.	24	$516
Amneal Pharmaceuticals LLC	30	$512
Corcept Therapeutics	20	$486
Xeris Pharmaceuticals, Inc.	25	$474
Mannkind Corporation	21	$337
Antares Pharma, Inc.	14	$271
Bayer	8	$250
Johnson & Johnson	8	$160
IBSA Pharma Inc.	8	$126
Merck	8	$124
Sequel Med Tech, LLC	5	$122
Ascensia Diabetes Care US Inc.	5	$107
Novartis	3	$105
Otsuka America Pharmaceutical, Inc.	1	$99
Ultragenyx Pharmaceutical Inc.	2	$87
Valeritas, Inc.	1	$79
Astellas Pharma US Inc	4	$68
Zealand Pharma US, Inc.	3	$66
Recordati_rare_diseases_inc.	3	$60
Lifescan, Inc.	4	$54
Azurity Pharmaceuticals, Inc.	2	$47
Ascendis Pharma Endocrinology Inc	2	$45
EUSA Pharma (US) LLC	2	$45
Amarin Pharma, Inc.	3	$43
Acella Pharmaceuticals, LLC	2	$42
Clarus Therapeutics Inc.	3	$38
Cequr Corporation	1	$37
Vistapharm, Inc.	2	$35
Rhythm Pharmaceuticals, Inc.	1	$30
Philips North America LLC	1	$30
BETA Bionics, Inc.	1	$30
Boston Scientific	1	$25
Averitas Pharma Inc.	1	$24
Madrigal Pharmaceuticals	1	$22
Senseonics, Incorporated	1	$21
Halozyme Inc	1	$19
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$16
Shire North American Group Inc	1	$15
Currax Pharmaceuticals LLC	1	$14

How this compares

$2,460,987 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024

$262,135

Medicare patients

1,017

Services billed

3,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Jacksonville

David SuttonJacksonville$3.1M
Mae Sheikh AliJacksonville$2.9M
James MageeJacksonville$2.7M
J EvansJacksonville$1.7M
Wasim DeebJacksonville$1.5M
Ricardo SilvaJacksonville$867K
Anil ShresthaJacksonville$602K
Joe ChehadeJacksonville$542K
Firas WardaJacksonville$440K
Khurram WadudJacksonville$338K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →